Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis

Richard T. Silver, William Chow, Attilio Orazi, Stephen P. Arles, Stanley J. Goldsmith

Blood (2013) 122 (11): 1881–1886.

https://doi.org/10.1182/blood-2013-06-508416

Published: 2013

Journal Articles

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy

Rebecca L. Elstrom, MD, John P. Leonard, MD, Paul Christos, Peter Martin, MD, Daniel Lebovic, MD, Joseph Osborne, Stanley J. Goldsmith, June Greenberg, RN, Richard R. Furman, MD, Jia Ruan, MD, PhD, Ryan Putman, Erica Chapman, Madhu Mazumdar, Kent A. Griffith, Morton Coleman, MD, Mark S. Kaminski, MD

Blood (2012) 120 (21): 1636.

https://doi.org/10.1182/blood.V120.21.1636.1636

Published: 2012

Journal Articles

Prospective Evaluation of the World Health Organization Criteria for the Diagnosis of Polycythemia Vera,

Richard T. Silver, MD, William Chow, Katherine Vandris, Ivy Tam, Anita Narayan, Maria Teresa De Sancho, MD, Attilio Orazi, MD, Stanley J. Goldsmith

Blood (2011) 118 (21): 3837.

https://doi.org/10.1182/blood.V118.21.3837.3837

Published: 2011

Journal Articles

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy,

Rebecca Elstrom, MD, John P. Leonard, MD, Stanley J. Goldsmith, Paul Christos, Peter Martin, Joseph Osborne, Daniel Lebovic, MD, Ramsey Abdallah, CRC, June Greenberg, Richard R. Furman, MD, Jia Ruan, MD, PhD, Kent A. Griffith, Morton Coleman, MD, Mark S. Kaminski, MD

Blood (2011) 118 (21): 3712.

https://doi.org/10.1182/blood.V118.21.3712.3712

Published: 2011

Journal Articles

Fludarabine Plus I-131 Tositumomab as Initial Treatment for Follicular Lymphoma: Half of Patients In Remission at Over 10 Years Median Followup.

Peter Martin, FRCPC, MD, MS, Morton Coleman, MD, Richard R. Furman, MD, Shankar Vallabhajosula, Dong Sun Kim, Andrew Edelstein, Julia Morrison, Rebecca Elstrom, MD, Jia Ruan, MD, PhD, Stanley J. Goldsmith, John P. Leonard, MD

Blood (2010) 116 (21): 1785.

https://doi.org/10.1182/blood.V116.21.1785.1785

Published: 2010

Journal Articles

Value of FDG-PET in Prediction of Splenectomy Findings in Patients with Suspected or Known Lymphoma.

Sarah C. Rutherford, Biree Andemariam, MD, Shibu M. Philips, MD, MPH, Amy Chadburn, MD, Richard R. Furman, MD, Morton Coleman, MD, Stanley J. Goldsmith, MD, John P. Leonard, MD

Blood (2006) 108 (11): 2405.

https://doi.org/10.1182/blood.V108.11.2405.2405

Published: 2006

Journal Articles

FDG-PET May Be Helpful in the Determination of Transformation to an Aggressive Subtype in Low-Grade Lymphoma.

Lale Kostakoglu, MD, Stanley J. Goldsmith, MD, Amy Chadburn, MD, Erez Vidan, MD, Michael Schuster, MD, Paul Christos, M.S., MPH, Morton Coleman, MD

Blood (2005) 106 (11): 1927.

https://doi.org/10.1182/blood.V106.11.1927.1927

Published: 2005

Journal Articles

FDG-PET Demonstrates Different Metabolic Activities among Lymphoma Subtypes.

Lale Kostakoglu, MD, Stanley J. Goldsmith, MD, Anjaly Chandramouly, BS, Erez Vidan, MD, Sumeet Verma, MD, Morton Coleman, MD.

Blood (2005) 106 (11): 4699.

https://doi.org/10.1182/blood.V106.11.4699.4699

Published: 2005

NARROW

Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy

Prospective Evaluation of the World Health Organization Criteria for the Diagnosis of Polycythemia Vera,

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy,

Fludarabine Plus I-131 Tositumomab as Initial Treatment for Follicular Lymphoma: Half of Patients In Remission at Over 10 Years Median Followup.

Value of FDG-PET in Prediction of Splenectomy Findings in Patients with Suspected or Known Lymphoma.

FDG-PET May Be Helpful in the Determination of Transformation to an Aggressive Subtype in Low-Grade Lymphoma.

FDG-PET Demonstrates Different Metabolic Activities among Lymphoma Subtypes.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only